Building a KOL Engagement Strategy:
How Medical Device Companies Turn Clinical Champions Into Commercial Momentum

In MedTech, no advertisement will ever be as persuasive as a respected physician telling a colleague, "I use this, and it works." Those anecdotes encompass the premise behind a KOL engagement strategy: identifying the clinicians whose opinions shape their specialty, and building relationships that turn their credibility into adoption, evidence, and revenue.

While most device companies understand this, far fewer act on it in a structured way. KOL outreach often amounts to a spreadsheet of names, a dinner at a conference, and an advisory board that meets twice and quietly dissolves. The companies that treat key opinion leader engagement as core commercial infrastructure, rather than a networking activity, consistently outpace the ones that improvise.

The following post explores why KOLs carry so much weight in device adoption, where most programs break down, and how to build a KOL engagement strategy that actually compounds.

Why KOL Engagement Matters More in MedTech Than Almost Anywhere Else

Physicians adopt new technology through evidence and through the people they trust, not through marketing claims. In one Sermo poll, 86% of physicians said a key opinion leader's credibility depends on professional credentials, experience, or recommendations from their peers.¹ Trust in MedTech flows through professional hierarchy and peer validation, and KOLs sit at the top of that network.

Exposure to KOL content is frequent and ongoing. Roughly 44% of physicians engage with KOL content several times a week, and another 36% do so weekly or bi-weekly.² Peer-reviewed research supports the implication that a physician's peer network measurably influences whether and how quickly they adopt new treatments.³

However, only a minority of physicians say an expert opinion alone directly changes their clinical decisions. The majority of physicians express that KOL perspectives prompt them to investigate the evidence themselves.⁴ In other words, KOLs open the door; your clinical data and commercial execution still have to walk through it. A KOL program is not a substitute for evidence or infrastructure. It is the multiplier on both.

Where Most KOL Engagement Strategies Break Down

When KOL programs underperform, the causes emerge as patterns across companies and specialties.

Engagement Starts Too Late

Many companies begin recruiting KOLs after clearance when the need for endorsements is immediate, but credibility cannot be rushed. The strongest advocates are clinicians who contributed input during development or trials and feel genuine ownership of the outcome. As with commercialization strategy as a whole, KOL engagement works best when it runs parallel to the regulatory process, not after it.

Companies Chase Titles Instead of Influence

The most published name in the field is not automatically your best advocate. National KOLs bring visibility, but adoption decisions often hinge on regional and local opinion leaders: the electrophysiologist whose colleagues across three hospital systems call for advice, or the surgeon who trains a dozen fellows a year. An effective program maps actual influence networks, not just citation counts.

The Relationship Is One-Way

If every interaction is a request (“speak here”, “endorse this”, “review that”), KOLs disengage. Sustained advocacy comes from genuine exchange: sharing data early, incorporating their feedback visibly, and giving them a real voice in the product's direction. KOLs can tell the difference between being consulted and being used.

Nothing Is Tracked

Without infrastructure, KOL engagement lives in one salesperson's inbox. Without a centralized system, the organization cannot see who talked to whom, what was promised, or which advocates are becoming less engaged. If that person leaves, the program leaves with them.

The Four Pillars of a KOL Engagement Strategy That Works

A durable KOL program is built, not assembled. The four pillars below work as a system: mapping identifies who matters, lifecycle alignment outlines what to ask and when, infrastructure keeps the relationships alive beyond any one employee, and measurement proves the program is earning its budget. Skip any one of them, and the others underperform.

1. Map the Right KOLs, Not Just the Famous Ones

Start with a tiered map. This should include national voices who shape guidelines and podium narratives, regional leaders who influence health system decisions, and local champions who drive day-to-day utilization. Score candidates on network influence, alignment with your clinical story, and willingness to engage. A focused roster of 15 genuinely engaged clinicians beats a list of 100 names every time.

2. Match Engagement to Your Lifecycle Stage

The right “ask” depends on where you are. Pre-clearance may include advisory boards, trial involvement, and design feedback. At launch, the focus shifts podium presence, peer-to-peer education, and case publications. During post-launch, it shifts to training programs, real-world evidence, and expansion into adjacent specialties. Companies that use the same playbook at every stage burn out their advocates early.

3. Build the Infrastructure to Sustain It

Every KOL interaction should live in your CRM: touchpoints, commitments, contracts, and engagement history visible across marketing, sales, and clinical teams. This is unglamorous work, but it separates a program from a collection of relationships. It also plays an important role for compliance, as KOL compensation and interactions in MedTech are regulated and must be documented at fair market value.

4. Measure What Matters

Consider outputs such as podium mentions, publications, proctored cases, referrals into new accounts, and advocate-influenced pipeline. If you cannot connect KOL activity to commercial outcomes, you cannot defend the budget, and you cannot improve the program.

What This Looks Like in Practice

When Conformal Medical, a Class III cardiology device company, closed its $35M Series D, Cicada built its KOL engagement program alongside email, social, and clinical trial infrastructure, standing up an electrophysiology KOL program with the CRM foundation to track and sustain it. The relationships and the systems were built together, creating a foundation for long-term success. You can read more in our case studies.

Frequently Asked Questions About KOL Engagement

Turning Clinical Credibility Into Commercial Results

A structured KOL engagement strategy is one of the highest-leverage investments a medical device company can make. The physicians who shape your specialty are already talking to each other about what works. The only question is whether your product is part of that conversation, and whether you have built the relationships, systems, and measurement to make it stick.

Start early, map real influence rather than titles, give as much as you ask, and put infrastructure behind all of it. That is how clinical champions become commercial momentum.